Serenis’ hybrid model connects people with qualified therapists through proprietary digital technology, tackling accessibility barriers and the stigma that often surround mental health disorders. At Angelini Ventures, mental health and brain health are a core priority. To date, Angelini Ventures has invested around €125 million into 22 companies covering a range of therapeutic areas and modalities. Angelini Ventures’ BioTech portfolio includes Elkedonia, Therini Bio, Nuevocor, Neumirna, Cour Pharmaceuticals, Nouscom, Pretzel Therapeutics and Freya Biosciences. The Company’s Digital Health portfolio includes Vantis Health, Avation, Cadence Neuroscience, Nobi, Noctrix and Serenis.